Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition

Abstract Background Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up. Management of patients progressing on first-line immunotherapy remains...

Full description

Bibliographic Details
Main Authors: Zoë Blake, Douglas K. Marks, Robyn D. Gartrell, Thomas Hart, Patti Horton, Simon K. Cheng, Bret Taback, Basil A. Horst, Yvonne M. Saenger
Format: Article
Language:English
Published: BMJ Publishing Group 2018-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Melanoma
Brain metastases
Talimogene laherparepvec
T-Vec
Checkpoint inhibitors
Anti-PD1
Online Access:http://link.springer.com/article/10.1186/s40425-018-0338-6

Internet

http://link.springer.com/article/10.1186/s40425-018-0338-6

Similar Items